HK1069335B - Use of anastrozole for the treatment of post-menopausal women having early breast cancer - Google Patents

Use of anastrozole for the treatment of post-menopausal women having early breast cancer Download PDF

Info

Publication number
HK1069335B
HK1069335B HK05101996.7A HK05101996A HK1069335B HK 1069335 B HK1069335 B HK 1069335B HK 05101996 A HK05101996 A HK 05101996A HK 1069335 B HK1069335 B HK 1069335B
Authority
HK
Hong Kong
Prior art keywords
anastrozole
tamoxifen
breast cancer
patients
treatment
Prior art date
Application number
HK05101996.7A
Other languages
German (de)
English (en)
Chinese (zh)
Other versions
HK1069335A1 (en
Inventor
Paul Plourde
Anthony Rogers
Brent Vose
Michael Dukes
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0129457.8A external-priority patent/GB0129457D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1069335A1 publication Critical patent/HK1069335A1/en
Publication of HK1069335B publication Critical patent/HK1069335B/en

Links

Claims (7)

  1. Utilisation d'anastrozole, ou d'un sel pharmaceutiquement acceptable de celui-ci, pour la préparation d'un médicament destiné à réduire le taux de récurrence d'un cancer chez une femme postménopausée atteinte d'un cancer du sein à un stade précoce.
  2. Utilisation d'anastrozole, ou d'un sel pharmaceutiquement acceptable de celui-ci, pour la préparation d'un médicament destiné à réduire le taux de nouvelle tumeur primaire controlatérale chez une femme postménopausée atteinte d'un cancer du sein à un stade précoce.
  3. Utilisation selon la revendication 1 ou la revendication 2, selon laquelle l'anastrozole est fourni en l'absence d'agent anti-oestrogène.
  4. Utilisation selon la revendication 3, selon laquelle l'agent anti-oestrogène est le tamoxifène.
  5. Utilisation selon l'une quelconque des revendications précédentes, selon laquelle la femme atteinte dudit cancer du sein à un stade précoce est positive pour les récepteurs aux oestrogènes ou positive pour les récepteurs à la progestérone.
  6. Utilisation selon la revendication 5, selon laquelle la femme atteinte dudit cancer du sein à un stade précoce est positive pour les récepteurs aux oestrogènes et positive pour les récepteurs à la progestérone.
  7. Utilisation selon l'une quelconque des revendications précédentes, selon laquelle l'anastrozole est administré à une dose de 1 mg/jour.
HK05101996.7A 2001-12-10 2002-12-06 Use of anastrozole for the treatment of post-menopausal women having early breast cancer HK1069335B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0129457.8 2001-12-10
GBGB0129457.8A GB0129457D0 (en) 2001-12-10 2001-12-10 Method of treatment
PCT/GB2002/005554 WO2003053438A1 (fr) 2001-12-10 2002-12-06 Utilisation de l'anastrozole pour le traitement du cancer du sein a un stade precoce chez les femmes menopausees

Publications (2)

Publication Number Publication Date
HK1069335A1 HK1069335A1 (en) 2005-05-20
HK1069335B true HK1069335B (en) 2009-04-24

Family

ID=

Similar Documents

Publication Publication Date Title
Paridaens et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer
JP2011016828A (ja) 早期乳癌を有する閉経後の女性の処置のためのアナストロゾールの使用
Kong et al. Phase 2 study of bortezomib combined with temozolomide and regional radiation therapy for upfront treatment of patients with newly diagnosed glioblastoma multiforme: safety and efficacy assessment
Goss et al. Aromatase inhibitors for chemoprevention
US20260041695A1 (en) Combination therapies for treatment of breast cancer
Campos et al. A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases
Harris et al. Aminoglutethimide for the treatment of advanced postmenopausal breast cancer
Burnett et al. Anastrozole, an aromatase inhibitor, and medroxyprogesterone acetate therapy in premenopausal obese women with endometrial cancer: a report of two cases successfully treated without hysterectomy
Jänicke Are all aromatase inhibitors the same? A review of the current evidence
US20210393630A1 (en) Endocrine therapy and abemaciclib combination for the adjuvant treatment of node-positive, early stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer
Chung et al. The role of aromatase inhibitors in early breast cancer
Tariq et al. Hormonal therapies in cancers
US20210346398A1 (en) Combinations with a c-19 steroid for treating cancers
HK1069335B (en) Use of anastrozole for the treatment of post-menopausal women having early breast cancer
AU2004281527A1 (en) Breast cancer treatment regimen
Tamaki et al. Aromatase inhibitors for treatment of postmenopausal patients with breast cancer
Gardella et al. Palliative treatment of endometrial cancer type 1 in elderly women with Anastrozole.
Smith The third-generation aromatase inhibitors
Kishan et al. Low rate of clinician-scored gynecomastia induced by 6 months of combined androgen blockade in a randomized trial: Implications for prophylactic breast irradiation
Dean Hormone treatment for breast cancer
Breul THERAPY OPTIMIZATION TRIAL OF A COMBINATION OF ORAL ESTRAMUSTINE PHOSPHATE (ESTRACYT®) AND ORAL ETOPOSIDE (VEPESID®) IN HORMONE RESISTANT METASTATIC PROSTATE CANCER
Wardley Endocrine Therapy in Breast Cancer Management
Santhanam et al. Antioestrogens and breast cancer